An outbreak of HCV genotype 6a and 2a infection in South China: Confirmation of iatrogenic transmission by phylogenetic analysis of the NS5B region

XIAOQIONG SHAO1*, QIUMIN LUO1*, QINGXIAN CAI1*, FULONG ZHANG2, JIANGYUN ZHU1, YING LIU1, ZHIXIN ZHAO1, ZHILIANG GAO1 and XIAOHONG ZHANG1

1Department of Infectious Disease, The Third Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510630; 2Department of Internal Medicine, Zijin County People's Hospital, Heyuan, Guangdong 517400, P.R. China

Received August 31, 2015; Accepted September 2, 2016

DOI: 10.3892/mmr.2016.5737

Abstract. An outbreak of hepatitis C virus (HCV) infections, for which the risk factor was unknown, was previously identified in North Guangdong, China. In the present study, a total of 736 local residents were surveyed regarding their lifetime risk factors for HCV infection. Serum anti‑HCV antibodies and HCV RNA were examined to confirm infection. In the HCV-positive samples, the core and nonstructural protein 5B sequences were amplified, and phylogenetic analysis was performed to determine the association between HCV subtypes and transmission routes. A total of 374 individuals were positive for anti‑HCV antibodies. Blood transfusion, blood product transfusion, people who inject drugs and intravenous injection at a local clinic were identified as independent risk factors for HCV infection. Phylogenetic analysis revealed that the two predominant subtypes of HCV, 2a and 6a, were primarily focused in four homologous clusters. Patients with a history of intravenous injection at a local clinic were more likely to be found in the four clusters, compared with patients exposed to other risk factors. The present emergency retrospective survey showed a specific epidemiological feature of HCV infection in Zijin County and found genetic homology among individuals exposed to intravenous injection at a local clinic. Further evidence is required to confirm the causal association between the outbreak of HCV infection and intravenous injection.

Introduction

Hepatitis C virus (HCV) infection is one of the primary causes of chronic liver disease worldwide (1). It is estimated that ~3% of the world's population is chronically infected with HCV (2), although the frequency of infection varies between populations and geographic regions (3). In Western Europe, the prevalence of HCV ranges between 0.4 and 3%. In Eastern Europe and the Middle East, the prevalence is higher, although the exact prevalence remains to be fully elucidated (4). The highest worldwide prevalence is in Egypt, which has a national prevalence of 9% and a prevalence of up to 50% in rural areas (5).

HCV is transmitted parenterally. Prior to the 1990s, the principal routes of HCV transmission were blood transfusion, intravenous drug use and unsafe injection procedures (6). In industrialized countries, these modes of transmission account for ~70% of HCV infections (6). Since 1992, screening of blood donors has essentially eradicated the transmission of HCV by transfusion. Currently, new HCV infections are caused by intravenous or nasal drug use and, to a lesser degree, unsafe medical or surgical procedures (7). Sexual transmission of HCV among men who have intercourse with men was also a major route of transmission, and data indicates that promiscuous male homosexual activity is associated with HCV infection (8).

China has a population of 1,300,000,000; the frequency of HCV infection has been reported to be 3.2% nationally and 3.1% in rural areas (9,10). However, the prevalence of HCV infection differs between regions (11). The transmission of HCV via contaminated blood was previously a serious issue in China. Between 1994 and 1996, a plasma campaign in Henan province resulted in the infection of 500,000 blood donors with HCV and the infection of 300,000 donors with human immunodeficiency virus (12‑15). Similar experiences were also reported in other provinces of China (14).

At present in China (since 1992), the principal routes of transmission for newly diagnosed HCV infections are blood transfusions, surgical procedures and intravenous drug use (16,17).

Guangdong is a province on the South China Sea coast of China. A previous study from a medical center in Guangdong...
province sampled 393 patients with chronic hepatitis C and showed that the predominant HCV subtypes were subtypes 1b, 6a, 2a, 3a and 3b, which accounted for 65.9, 17.1, 7.4, 3.6 and 3.3% of cases, respectively (18).

Zijin County is located in the north of Guangdong province and has a population of ~800,000. The present study focussed on a previous outbreak in which dozens of cases of HCV infection were newly diagnosed in the same local street. It did not appear that the principle routes of HCV transmission, including blood transfusion or intravenous drug use, were responsible for this outbreak. To determine the transmission routes of this specific outbreak, the present study conducted an emergency survey of the region.

Materials and methods

Study design. In late February 2012, an emergency survey was conducted to investigate the HCV epidemic of Xiangshui Road in Zijin County, Heyuan. A questionnaire regarding lifetime risk factors for HCV infection was administered to all local residents. Blood samples were obtained from all respondents (n=736) and the serum was separated from the samples by centrifugation (2,200 x g, 10 min, 4°C). Healthcare workers from a recently closed local medical clinic were interviewed regarding procedures at the clinic. Informed consent was obtained from all participants. The present study was performed in accordance with the 1964 Declaration of Helsinki and later amendments. The protocol was approved by the ethics committee of the Third Affiliated Hospital of Sun Yat-Sen University (Guangzhou, China).

Analysis of serum samples

Determination of HCV infection. An HCV enzyme immunoassay (HCV EIA 3.0; Abbott GmbH, Wiesbaden, Germany) was used to detect anti-HCV antibodies in the serum samples. Individuals positive for anti-HCV antibodies were further assessed for the presence of HCV RNA using the COBAS AMPLICOR HCV Monitor 2.0 assay (Roche Diagnostics, Branchburg, NJ, USA). If the result was negative, a second serum sample was acquired from the respondents (n=736) and the serum was separated from the samples by centrifugation (2,200 x g, 10 min, 4°C). Healthcare workers from a recently closed local medical clinic were interviewed regarding procedures at the clinic. Informed consent was obtained from all participants. The present study was performed in accordance with the 1964 Declaration of Helsinki and later amendments. The protocol was approved by the ethics committee of the Third Affiliated Hospital of Sun Yat-Sen University (Guangzhou, China).

Sequencing of HCV RNA. The HCV RNA was extracted from serum samples identified as positive for HCV RNA. HCV RNA sequencing was performed as described previously (19). In brief, the HCV RNA was extracted from the serum samples using the RNAiso™ Plus extraction kit (Takara Biotechnology Co., Ltd., Dalian, China). The HCV RNA was then reverse transcribed into cDNA using the ReverTra Ace-ρ-rainbow qPCR Master Mix (Toyobo, Osaka, Japan). The cDNA was then ampliﬁed using nested PCR. The PCR conditions were as follows: 94°C for 5 min; followed by 30 cycles at 94°C for 30 sec, 55°C for 1 min and 72°C for 10 min; and a final step at 72°C for 10 min. DNA was sequenced in both directions using an ABI Prism 3,730 genetic analyzer (Applied Biosystems; Thermo Fisher Scientiﬁc, Inc., Waltham, MA, USA). The experiment was performed twice, at an interval of 2 months, to conﬁrm the results.

Phylogenetic analysis of core and NS5B alignments. The sequences of the HCV strains were aligned using the ClustalW 1.8 software package (20), with a reference panel of sequences representative of each subtype (21) retrieved from the HCV database (http://hcv.lanl.gov/content/index). Prior to phylogenetic analysis, the jModeltest program (22) was used to determine the optimal substitution model based on the Akaike information criterion (23). The results indicated that K2+G was the optimal model for the Core-E1 and NS5B datasets. Under this model, maximum-likelihood trees were estimated using the subtree pruning and regrafting and nearest neighbor interchange algorithms in PhyML (24). Bootstrap support values (1,000 repetitions) of >70% were accepted as deﬁning clusters.

Statistical analysis. Differences between groups were examined using a χ² test. To identify the factors signiﬁcantly associated with HCV infection, univariate logistic regression analysis was performed, and the variables with P<0.15 in unvariable analysis were selected for multiple binary logistic regression analyses with backwards elimination forced in the final model. Statistical analysis was performed using SPSS version 19.0 (IBM SPSS, Armonk, NY, USA). P<0.05 was considered to indicate a statistically signiﬁcant difference.

Results

HCV infection and risk factors. A total of 736 residents from Xiangshui Road, Zijin, Guangdong, were included in the survey. The included residents had an average age of 40±19.6 years old (range, 4-90 years old) and 51.4% were men (378 respondents). The 736 residents included in the survey, 50.8% were positive for the anti-HCV antibody. The characteristics of the HCV-positive and HCV-negative survey respondents are shown in Table I.

Using univariate logistic regression analysis, the exposure of an individual to a number of risk factors, including blood product transfusion, intravenous injection at a local clinic and ≥2 infected family members, were signiﬁcantly associated with the risk of HCV infection. Gender, age, HBV surface antigen (HBSAg), blood donor history, blood transfusion history, intravenous drug use, surgery history, dental visit history and number of sexual partners were not signiﬁcantly associated.
with the risk of HCV infection. Of the infected patients, 86.6% (324/374) had multiple risk factors, and 86.7% (85/98) of the individuals with ≥2 family members infected with HCV had a history of intravenous injection at a local clinic. To further examine the association between risk factors and HCV infection, multivariate logistic regression analysis was performed (Table II). Following adjustment for blood transfusions, blood product transfusion, intravenous drug use and intravenous injection, the number of family members infected with HCV was not a significant risk factor for HCV infection.

A total of 53.8% (396/736) of the survey respondents indicated a history of visiting a local clinic where they had received intravenous injection. The clinic had closed 3 months prior to the initiation of the survey. When the healthcare workers from the closed clinic were interviewed, they stated that they had reused glass syringes for intravenous injections and that equipment was cleaned through scalding. Following each injection, the needle and syringe were washed by filling it with clean water several times and shaking vigorously for 30 sec. This cleaning process was repeated twice. The syringe was later detached from the needle and boiled for 15 min with 2% sodium carbonate for 15 min. However, this procedure was not always observed by the survey respondents, particularly when there were numerous patients attending the clinic.

Table I. Univariate and multivariate logistic regression analyses of risk factors associated with HCV infection.

<table>
<thead>
<tr>
<th>Characteristics and risk factors</th>
<th>HCV positive (n=374)</th>
<th>HCV negative (n=362)</th>
<th>Crude OR (95% CI)</th>
<th>P-value</th>
<th>Adjusted OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>182 (48.7%)</td>
<td>193 (53.3%)</td>
<td>0.83 (0.62-1.11)</td>
<td>0.207</td>
<td>0.83 (0.62-1.11)</td>
<td>0.207</td>
</tr>
<tr>
<td>Age (≥40 years old)</td>
<td>205 (54.8%)</td>
<td>184 (50.8%)</td>
<td>1.17 (0.88-1.57)</td>
<td>0.279</td>
<td>1.37 (0.94-1.99)</td>
<td>0.100</td>
</tr>
<tr>
<td>HBsAg</td>
<td>28 (7.5%)</td>
<td>29 (8.0%)</td>
<td>0.93 (0.54-1.60)</td>
<td>0.790</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood donor</td>
<td>19 (5.1%)</td>
<td>23 (6.4%)</td>
<td>0.79 (0.42-1.48)</td>
<td>0.457</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>22 (5.9%)</td>
<td>12 (3.3%)</td>
<td>1.82 (0.89-3.7)</td>
<td>0.097</td>
<td>9.14 (4.04-20.67)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Blood product</td>
<td>45 (12.0%)</td>
<td>27 (7.5%)</td>
<td>1.70 (1.03-2.80)</td>
<td>0.037</td>
<td>2.99 (1.54-5.78)</td>
<td>0.001</td>
</tr>
<tr>
<td>Drug use (injection)</td>
<td>14 (3.7%)</td>
<td>7 (1.9%)</td>
<td>1.97 (0.79-4.94)</td>
<td>0.140</td>
<td>14.98 (5.52-40.64)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Surgery history</td>
<td>28 (7.5%)</td>
<td>34 (9.4%)</td>
<td>0.78 (0.46-1.32)</td>
<td>0.352</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous injection&lt;sup&gt;a&lt;/sup&gt;</td>
<td>303 (81.0%)</td>
<td>93 (25.7%)</td>
<td>12.34 (8.70-17.51)</td>
<td>&lt;0.001</td>
<td>20.63 (13.64-31.21)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Visited a dentist</td>
<td>36 (9.6%)</td>
<td>32 (8.8%)</td>
<td>1.10 (0.67-1.81)</td>
<td>0.713</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family infection&lt;sup&gt;b&lt;/sup&gt;</td>
<td>98 (26.2%)</td>
<td>55 (15.2%)</td>
<td>1.98 (1.37-2.86)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexual history&lt;sup&gt;c&lt;/sup&gt;</td>
<td>14 (3.7%)</td>
<td>11 (3.0%)</td>
<td>1.24 (0.56-2.77)</td>
<td>0.598</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Respondents were defined as HCV positive if samples were positive for anti-HCV antibodies or the presence of HCV RNA. Variables selected in the final model were determined by backwards stepwise elimination. *Respondents received intravenous injection from a clinic in which glass syringes were reused. †Respondents had ≥2 family members infected with HCV. ‡Respondents had a history of ≥2 sexual partners. HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval; HBsAg, hepatitis B virus surface antigen.

Table II. Univariate and multivariate logistic regression analyses of risk factors associated with a positive HCV result.

<table>
<thead>
<tr>
<th>Characteristics and risk factors</th>
<th>HCV RNA (+) (n=264)</th>
<th>HCV RNA (‑) (n=110)</th>
<th>Crude OR (95% CI)</th>
<th>P-value</th>
<th>Adjusted OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>126 (47.7)</td>
<td>56 (50.9)</td>
<td>0.88 (0.56-1.37)</td>
<td>0.575</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (≥40 years old)</td>
<td>156 (59.1)</td>
<td>44 (40.0)</td>
<td>3.42 (2.07-5.65)</td>
<td>&lt;0.001</td>
<td>2.24 (1.38-3.64)</td>
<td>0.001</td>
</tr>
<tr>
<td>HBsAg</td>
<td>20 (7.6)</td>
<td>8 (7.3)</td>
<td>1.05 (0.45-2.45)</td>
<td>0.919</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>15 (5.7)</td>
<td>7 (6.4)</td>
<td>0.89 (0.35-2.24)</td>
<td>0.798</td>
<td>0.89 (0.30-2.61)</td>
<td>0.832</td>
</tr>
<tr>
<td>Blood product</td>
<td>29 (11.0)</td>
<td>16 (14.5)</td>
<td>0.73 (0.38-1.40)</td>
<td>0.335</td>
<td>0.68 (0.35-1.34)</td>
<td>0.265</td>
</tr>
<tr>
<td>Drug use (injection)</td>
<td>9 (3.4)</td>
<td>8 (7.3)</td>
<td>0.45 (0.17-1.20)</td>
<td>0.102</td>
<td>0.64 (0.173-2.37)</td>
<td>0.504</td>
</tr>
<tr>
<td>Intravenous injection&lt;sup&gt;a&lt;/sup&gt;</td>
<td>225 (85.2)</td>
<td>78 (70.9)</td>
<td>2.37 (1.39-4.04)</td>
<td>0.001</td>
<td>1.64 (0.80-3.37)</td>
<td>0.177</td>
</tr>
</tbody>
</table>

Respondents were defined as HCV RNA positive if samples were positive for HCV RNA. Gender, age, HBsAg status and associated risk factors (Table I) were selected as variables in the multivariate logistic regression analyses. *Respondents received intravenous injection from a clinic in which glass syringes were reused. HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval; HBsAg, hepatitis B virus surface antigen.

with the risk of HCV infection. Of the infected patients, 86.6% (324/374) had multiple risk factors, and 86.7% (85/98) of the individuals with ≥2 family members infected with HCV had a history of intravenous injection at a local clinic. To further examine the association between risk factors and HCV infection, multivariate logistic regression analysis was performed (Table II). Following adjustment for blood transfusions, blood product transfusion, intravenous drug use and intravenous injection, the number of family members infected with HCV was not a significant risk factor for HCV infection.

A total of 53.8% (396/736) of the survey respondents indicated a history of visiting a local clinic where they had received intravenous injection. The clinic had closed 3 months prior to the initiation of the survey. When the healthcare workers from the closed clinic were interviewed, they stated that they had reused glass syringes for intravenous injections and that equipment was cleaned through scalding. Following each injection, the needle and syringe were washed by filling it with clean water several times and shaking vigorously for 30 sec. This cleaning process was repeated twice. The syringe was later detached from the needle and boiled for 15 min with 2% sodium carbonate for 15 min. However, this procedure was not always observed by the survey respondents, particularly when there were numerous patients attending the clinic.

Positivity for HCV RNA. The 374 respondents who were positive for anti-HCV antibodies were examined for the presence of HCV RNA using reverse transcription-polymerase chain reaction analysis. The results showed that 264 (70.5%) were positive for HCV RNA.
In the HCV RNA-positive survey respondents, only age was significantly associated with the risk of being HCV RNA positive (odds ratio, 2.22; 95% confidence interval, 1.41-3.50; P<0.001). In the multivariate logistic regression analysis, having ≥2 sexual partners, or exposure to intravenous injection, intravenous drug use, blood product transfusion or blood transfusion were not found to be significantly associated with the risk of a positive HCV RNA result.

**HCV subtype and phylogenetic grouping.** RNA was extracted from the serum of the survey respondents identified as positive for the presence of HCV RNA (264 samples). Core and NS5B sequences were amplified successfully in 237 and 222 cases, respectively. Core and NS5B sequences were obtained in 213 respondents, core sequences were obtained in 24 respondents and NS5B sequences were obtained in nine respondents. Together, the amplification of either or both sequence regions was successful in 246 cases.

A total of four HCV subtypes were identified in the HCV RNA-positive samples: Subtype 1b in nine (3.7%) cases, subtype 2a in 84 (34.1%) cases, subtype 3b in two (0.8%) cases and subtype 6a in 151 (61.4%) cases. The genotypes

![Figure 1. Categorization of cases of HCV by suspected risk factor. Two clusters of HCV subtype 2a were identified in the survey respondents. The HCV subtype 2a phylogeny was estimated from the NS5B, nonstructural protein 5B region sequences. The HCV subtype 2b sequence was included as a negative control. Blue circles indicate HCV reference sequences from outside China; red circles are indicative of HCV reference sequences from other studies in China (origin country and accession numbers in GenBank are shown). Sequences with triangles are unique to the present study (Genbank accession nos. KJ416703-KJ416924). Sequences connected by blue and red lines, surrounded by the black dashed circles are indicative of cluster A (11 cases) and cluster B (63 cases). Sequences connected by green lines are indicative of sequences not in cluster A or B (four cases). Bootstrap support values are shown as percentages. HCV, hepatitis C virus.]
Table III. Hepatitis C virus subtype distribution by risk factor.

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Subtype 2a</th>
<th>Subtype 6a</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cluster A</td>
<td>Cluster B</td>
</tr>
<tr>
<td>Other risk factors&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Blood product transfusion</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Drug use (injection)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Intravenous injection&lt;sup&gt;b&lt;/sup&gt;</td>
<td>9</td>
<td>55</td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
<td>62</td>
</tr>
</tbody>
</table>

Data are representative of cases in which nonstructural protein 5B was successfully amplified and phylogenetically analyzed. <sup>a</sup>Other risk factors included blood donor history, surgery history, dental visit history and sexual history. <sup>b</sup>Intravenous injection at a local clinic.

determined by the core sequences were consistent with those determined by NS5B sequences.

HCV subtypes 2a and 6a were further analyzed through the generation of NS5B trees, since these subtypes accounted for 95.5% of genotypes confirmed. The NS5B sequences of subtype 2a were grouped into clusters A and B, which contained the sequences of 11 and 63 samples, respectively (Fig. 1). The bootstrap scores of clusters A and B were 71 and 77%, respectively. The NS5B sequences of subtype 6a were grouped into cluster C and D, which contained the sequences of 20 and 112 samples, respectively (Fig. 2). The bootstrap scores of cluster C and D were 73 and 81%, respectively. The patients exposed to intravenous injection were more likely to distribute in clusters A, B, C and D, compared with those exposed to other risk factors (179/186, vs. 23/36; P<0.001; Table III).

**Discussion**

An outbreak of HCV infection was identified on a single road, Xiangshui Road, Zijin, Guangdong. Of the 736 respondents of the survey distributed to local residents, 50.8% were HCV-seropositive. Analysis of the risk factors for HCV infection among the survey respondents found that blood transfusion, intravenous drug use and intravenous injection at a local clinic were associated with HCV infection. Phylogenetic analysis of HCV NS5B sequences identified four clusters, suggesting a common mode of transmission, with the majority of patients reporting injection at a local clinic. The present study hypothesized that transmission may have occurred through unsafe injection practices.

In the present study, blood donation, surgery, dental visits, and having ≥2 sexual partners were not significantly associated with HCV infection. In China, paid blood donation has been banned since 1998, and HCV infection rates in blood donors have decreased from 12.87 to 1.71% (25,26). HCV screening prior to surgery has been routine practice since 1992, thus transmission of HCV via surgery or dental care is well controlled. It is known that sexual transmission of HCV accounts for <5% of HCV infections (27), as HCV is rarely present in semen or vaginal fluid. The risk of HCV infection for an individual who is in an unprotected sexual relationship with an HCV-infected individual for 20 years is 2.5% (28).

Although it has been reported that the prevalence of HCV infection in the intravenous drug use population was 61.4% in China (9), and the infection rate was substantially higher in southwestern China, only a marginal proportion of the survey respondents had a history of intravenous drug use (21/736). These results suggested that blood donation, surgery, dental visits and having ≥2 sexual partners were not the primary routes of HCV transmission in the individuals in the present study.

The spontaneous clearance of HCV occurs in 15-30% of cases of acute HCV (29) and is associated with interleukin 28B gene variation (30,31). The frequency of the rs12979860 C allele, which contributes to viral clearance in the Chinese Han population ranges between 74 and 98% (32). Thus, it may be that 70.5% of the anti-HCV antibody-positive respondents who were HCV RNA-positive in the present study was a result of spontaneous clearance.

HCV has been classified into seven genotypes and 82 subtypes (http://talk.ictvonline.org/ictv_wikis/wsg_flavi35. table-1-confirmed-hcv-genotypessubtypes-november-2014.aspx). Genotypes differ from each other by 31-33% at the nucleotide level, whereas subtypes differ by 20-25% (33). Despite the genetic diversity of HCV, all genotypes share collinearity in the large open reading frame, and the genetic associations of HCV variants consistent throughout the genome (33). Through genotyping of the HCV core and NS5B sequences of the infected patients, the present study showed that the genotypes determined by core sequences were consistent with those determined by NS5B sequences.

HCV genotypes have varied geographic distribution patterns. HCV subtypes 1a, 1b, 2a, 2b and 3a are distributed globally, whereas all other subtypes are restricted predominantly to certain geographic regions. Genotype 6 and its subtypes are found predominantly in Southeast Asia (34). Studies in Southern China have reported that HCV-6a accounts for 49.7% of cases detected in blood donors and 17.1% in patients with chronic HCV infection, and its overall proportion is increasing (35,36). In Guangdong, the predominant HCV subtypes in patients with chronic HCV are subtypes 1b, 6a, 2a, 3a and 3b (18). However, the genotypic distribution in the present study, which predominantly consisted of genotype...
SHAO et al.: OUTBREAK OF HCV GENOTYPE 6a AND 2a INFECTION BY IATROGENIC TRANSMISSION

4290

It has been shown that different genotypes are transmitted by different routes. For example, blood transfusion and surgery are more common risk factors for HCV infection by genotypes 1 and 2. By contrast, blood transfusion and surgery are less common risk factors for infection by genotypes 3 or 6 and lifestyle-associated risk factors, including intravenous drug use, tattoos and piercings, are more common risk factors (32). The subtypes found in the present study were clustered into four homologous groups, and the majority of patients who reported a history of intravenous injection at a local clinic were allocated into these four homologous clusters. The consistency between the epidemiological history and the results of the phylogenetic analysis may indicate a causal association.

As the clinic had closed, it was not possible to confirm intravenous procedures by the healthcare workers. From interviews with former employees of the clinic, it was revealed that intravenous injections were performed using reused glass syringes. As HCV is able to survive outside the body for at least 4 days and the virus is able to survive for weeks in blood

Figure 2. Identification of two clusters of HCV subtype 6a in the survey respondents. The HCV subtype 6a phylogeny was estimated from the NS5B, nonstructural protein 5B region sequences. The HCV subtype 6k was included as a negative control. Blue circles indicate HCV reference sequences from outside China; red circles indicate HCV reference sequences from other studies in China (origin country and Genbank accession numbers shown). Sequences with triangles are unique to the present study (GenBank accession nos. KJ416703-KJ416924). Sequences connected by blue and red lines, surrounded by black dashed circles are indicative of cluster C (20 cases) and cluster D (112 cases). Sequences connected by green lines are indicative of sequences not in cluster C or D (5 cases). Bootstrap support values are shown as percentages. HCV, hepatitis C virus.
This study was supported by funding from the National Science and Technology Major Project (grant no. 2012ZX10002003) and the Sun Yat-Sen University Clinical Research 5010 Program (grant no. 20100101).

Acknowledgements

This study was supported by funding from the National Science and Technology Major Project (grant no. 2012ZX10002003) and the Sun Yat-Sen University Clinical Research 5010 Program (grant no. 20100101).

References


